Outcomes in Bimekizumab Treated Psoriasis Patients With Prior IL-17 Inhibitor Failure.

Area of Science:

• Dermatology
• Immunology
• Pharmacology

Background:

• Biologic therapies, including IL-17 inhibitors, are crucial for moderate-to-severe psoriasis.
• Treatment discontinuation due to lack of efficacy or intolerance is common.
• Conventional strategies involve inter-class switching for primary non-responders and intra-class switching for secondary non-responders.

Purpose of the Study:

• To evaluate the real-world effectiveness of bimekizumab in patients with moderate-to-severe psoriasis who have previously failed IL-17 inhibitor therapy.
• To assess if bimekizumab can achieve stringent efficacy benchmarks (IGA 0/1, sPGAxBSA 100) in this patient population.
• To challenge conventional class-switching paradigms based on response type.

Main Methods:

• Retrospective analysis of 50 patients with moderate-to-severe psoriasis who failed prior IL-17 inhibitor therapy.
• Treatment with bimekizumab was administered.
• Efficacy was assessed using Investigator's Global Assessment (IGA) score and static Physician's Global Assessment multiplied by Body Surface Area (sPGAxBSA).

Main Results:

• 82% of patients achieved an IGA score of 0 or 1 (clear or almost clear skin).
• Stringent efficacy benchmarks were met, indicating significant clinical improvement.
• Bimekizumab demonstrated effectiveness in a challenging patient group with prior treatment failures.

Conclusions:

• Bimekizumab is a viable therapeutic option for patients with moderate-to-severe psoriasis who have not responded adequately to or are intolerant of prior IL-17 inhibitors.
• The study findings support considering bimekizumab even in patients previously classified as primary non-responders to IL-17 inhibitors.
• Real-world data support the efficacy of bimekizumab in a difficult-to-treat psoriasis population, potentially broadening treatment options beyond conventional switching strategies.